Cargando…

Intra-image referencing for simplified assessment of HER2-expression in breast cancer metastases using the Affibody molecule ABY-025 with PET and SPECT

PURPOSE: In phase I/II-studies radiolabelled ABY-025 Affibody molecules identified human epidermal growth factor receptor 2 (HER2) expression in breast cancer metastases using PET and SPECT imaging. Here, we wanted to investigate the utility of a simple intra-image normalization using tumour-to-refe...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandberg, Dan, Tolmachev, Vladimir, Velikyan, Irina, Olofsson, Helena, Wennborg, Anders, Feldwisch, Joachim, Carlsson, Jörgen, Lindman, Henrik, Sörensen, Jens
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486836/ https://www.ncbi.nlm.nih.gov/pubmed/28261749 http://dx.doi.org/10.1007/s00259-017-3650-3

Ejemplares similares

Measuring HER2-Receptor Expression In Metastatic Breast Cancer Using [(68)Ga]ABY-025 Affibody PET/CT
por: Sörensen, Jens, et al.
Publicado: (2016)

Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer
por: Alhuseinalkhudhur, Ali, et al.
Publicado: (2020)

Human Epidermal Growth Factor Receptor 2–Targeting [(68)Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer
por: Alhuseinalkhudhur, Ali, et al.
Publicado: (2023)

Optimized, automated and cGMP-compliant synthesis of the HER2 targeting [(68)Ga]Ga-ABY-025 tracer
por: Jussing, Emma, et al.
Publicado: (2023)

Radionuclide Therapy of HER2-Expressing Xenografts Using [(177)Lu]Lu-ABY-027 Affibody Molecule Alone and in Combination with Trastuzumab
por: Liu, Yongsheng, et al.
Publicado: (2023)

Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody(®) Molecules (177)Lu-ABY-271 and (177)Lu-ABY-027: Impact of DOTA Position on ABD Domain
por: Liu, Yongsheng, et al.
Publicado: (2021)

Affibody-mediated PET imaging of HER3 expression in malignant tumours
por: Rosestedt, Maria, et al.
Publicado: (2015)

Preclinical Evaluation of (99m)Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake
por: Oroujeni, Maryam, et al.
Publicado: (2021)

Affibody Molecules as Targeting Vectors for PET Imaging
por: Tolmachev, Vladimir, et al.
Publicado: (2020)

Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasis
por: Klint, Susanne, et al.
Publicado: (2023)

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution
por: Ding, Haozhong, et al.
Publicado: (2021)

Influence of Residualizing Properties of the Radiolabel on Radionuclide Molecular Imaging of HER3 Using Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

Improved contrast of affibody-mediated imaging of HER3 expression in mouse xenograft model through co-injection of a trivalent affibody for in vivo blocking of hepatic uptake
por: Rosestedt, Maria, et al.
Publicado: (2019)

Phase I clinical evaluation of (99m)Tc-labeled Affibody molecule for imaging HER2 expression in breast cancer
por: Bragina, Olga, et al.
Publicado: (2023)

Optimization of HER3 expression imaging using affibody molecules: Influence of chelator for labeling with indium-111
por: Rinne, Sara S., et al.
Publicado: (2019)

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with (64)Cu Using NOTA and NODAGA
por: Tolmachev, Vladimir, et al.
Publicado: (2017)

Site-Specific Radioiodination of HER2-Targeting Affibody Molecules using 4-Iodophenethylmaleimide Decreases Renal Uptake of Radioactivity
por: Strand, Joanna, et al.
Publicado: (2015)

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody–DM1 Drug Conjugates
por: Ding, Haozhong, et al.
Publicado: (2019)

[(68)Ga]ABY-028: an albumin-binding domain (ABD) protein-based imaging tracer for positron emission tomography (PET) studies of altered vascular permeability and predictions of albumin-drug conjugate transport
por: Jussing, Emma, et al.
Publicado: (2020)

Cellular Effects of HER3-Specific Affibody Molecules
por: Göstring, Lovisa, et al.
Publicado: (2012)

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2
por: Xu, Tianqi, et al.
Publicado: (2022)

In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct
por: Bass, Tarek Z., et al.
Publicado: (2017)

Benefit of Later-Time-Point PET Imaging of HER3 Expression Using Optimized Radiocobalt-Labeled Affibody Molecules
por: Rinne, Sara S., et al.
Publicado: (2020)

Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule (188)Re-ZHER2:41071
por: Liu, Yongsheng, et al.
Publicado: (2022)

Influence of Molecular Design on the Targeting Properties of ABD-Fused Mono- and Bi-Valent Anti-HER3 Affibody Therapeutic Constructs
por: Altai, Mohamed, et al.
Publicado: (2018)

HER3 PET Imaging: (68)Ga-Labeled Affibody Molecules Provide Superior HER3 Contrast to (89)Zr-Labeled Antibody and Antibody-Fragment-Based Tracers
por: Rinne, Sara S., et al.
Publicado: (2021)

Discovery, optimization and biodistribution of an Affibody molecule for imaging of CD69
por: Persson, Jonas, et al.
Publicado: (2021)

Molecular Design of HER3-Targeting Affibody Molecules: Influence of Chelator and Presence of HEHEHE-Tag on Biodistribution of (68)Ga-Labeled Tracers
por: Dahlsson Leitao, Charles, et al.
Publicado: (2019)

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model
por: Xu, Tianqi, et al.
Publicado: (2020)

Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model
por: Dahlsson Leitao, Charles, et al.
Publicado: (2020)

Biologic Evaluation of a Heterodimeric HER2-Albumin Targeted Affibody Molecule Produced by Chemo-Enzymatic Peptide Synthesis
por: Liu, Yongsheng, et al.
Publicado: (2022)

Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapy
por: Vorobyeva, Anzhelika, et al.
Publicado: (2018)

17AAG-induced internalisation of HER2-specific Affibody molecules
por: Göstring, Lovisa, et al.
Publicado: (2016)

Immunomodulatory activity of IR700-labelled affibody targeting HER2
por: Mączyńska, Justyna, et al.
Publicado: (2020)

Molecular design of radiocopper-labelled Affibody molecules
por: Tolmachev, Vladimir, et al.
Publicado: (2018)

PET of HER2 Expression with a Novel (18)FAl Labeled Affibody
por: Xu, Yuping, et al.
Publicado: (2017)

Increase in negative charge of (68)Ga/chelator complex reduces unspecific hepatic uptake but does not improve imaging properties of HER3-targeting affibody molecules
por: Rinne, Sara S., et al.
Publicado: (2019)

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
por: Yin, Wen, et al.
Publicado: (2021)

Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant Tumors
por: Honarvar, Hadis, et al.
Publicado: (2016)

Peripheral nerve injury grading simplified on MR neurography: As referenced to Seddon and Sunderland classifications
por: Chhabra, Avneesh, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_egdovpjnkrpb7kdf2msvcdtqvm